<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="224">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364090</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1007</org_study_id>
    <nct_id>NCT01364090</nct_id>
  </id_info>
  <brief_title>A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3</brief_title>
  <acronym>ACTIVATE</acronym>
  <official_title>A Phase IV, Open-label, Multicentre, International Trial of Response Guided Treatment With Directly Observed Pegylated Interferon Alfa 2b and Self Administered Ribavirin for Patients With Chronic HCV Genotype 2 or 3 and Injection Drug Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>Finland: Ethics Committee</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Norway: Regional Ethics Commitee</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and
      effective for patients who are current injection drug users or receiving opiate substitution
      therapy and who are responding well to treatment early on.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the feasibility, safety and effectiveness of shortened treatment for
      hepatitis C genotypes 2/3 in current injection drug users or receiving opiate substitution
      therapy. Treatment will be with pegylated interferon alfa 2b (directly observed) and
      ribavirin for 12 weeks in those that have non-quantifiable (&lt;15 IU/ml detected and &lt;15 IU/ml
      undetected) HCV RNA or undetectable HCV RNA on qualitative assay at week 4 and 24 weeks in
      those that have quantifiable (≥15 IU/ml) HCV RNA or detectable HCV RNA on qualitative assay
      at week 4.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Treatment Efficacy</measure>
    <time_frame>36 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure is the proportion of patients with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following directly observed PEG-IFN alfa-2b in combination with self-administered ribavirin for 12 weeks in participants with non-quantifiable (&lt;15 IU/ml detected and &lt;15 IU/ml undetected) HCV RNA or undetectable HCV RNA on qualitative assay at week 4 of therapy and for 24 weeks in participants with quantifiable (≥15 IU/ml) HCV RNA or detectable HCV RNA on qualitative assay at week 4 of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the safety and tolerability of directly observed PEG-IFN alfa-2b in combination with self-administered ribavirin for 12 weeks in participants with non-quantifiable HCV RNA or undetectable HCV RNA on qualitative assay at week 4 of therapy and for 24 weeks in participants with quantifiable HCV RNA or detectable HCV RNA on qualitative assay at week 4 of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Adherence</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the adherence (&gt;80 of PEG-IFN, &gt;80% of RBV, &gt;80% of time) to directly observed PEG-IFN alfa-2b in combination with self-administered ribavirin for 12 weeks in participants with non-quantifiable HCV RNA or undetectable HCV RNA on qualitative assay at week 4 of therapy and for 24 weeks in participants with quantifiable HCV RNA or detectable HCV RNA on qualitative assay at week 4 of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response (ETR &amp; SVR24)</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the percentage with undetectable HCV RNA at end of treatment (ETR) and 24 weeks post end of treatment (SVR24) in participants treated with PEG-IFN alfa-2b in combination with self-administered ribavirin for 12 weeks in participants with non quantifiable HCV RNA or undetectable HCV RNA at week 4 of therapy and for 24 weeks in participants with quantifiable HCV RNA or detectable HCV RNA at week 4 of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral and Quality of Life</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate changes in illicit drug use, opiate substitution therapy, depression, suicidal ideations and health-related quality of life in participants treated with PEG-IFN alfa-2b in combination with self-administered ribavirin for 12 weeks in participants with non-quantifiable HCV RNA or undetectable HCV RNA on qualitative assay at week 4 of therapy and for 24 weeks in participants with quantifiable HCV RNA or detectable HCV RNA at week 4 of therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Standard Treatment Duration (24 weeks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shortened Treatment Duration (12 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa 2b</intervention_name>
    <description>Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.</description>
    <arm_group_label>Standard Treatment Duration (24 weeks)</arm_group_label>
    <arm_group_label>Shortened Treatment Duration (12 Weeks)</arm_group_label>
    <other_name>PegInteron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.</description>
    <arm_group_label>Standard Treatment Duration (24 weeks)</arm_group_label>
    <arm_group_label>Shortened Treatment Duration (12 Weeks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

          -  chronic HCV infection

          -  HCV genotype 2/3 infection

          -  active injection drug use (within 24 weeks prior to consent) or currently receiving
             opiate substitution therapy

          -  compensated liver disease

          -  negative pregnancy test (within 24 hours of first dose of study medication)

          -  effective contraception for the duration of the study

          -  written informed consent

        Exclusion Criteria:

          -  previous interferon or ribavirin therapy

          -  investigation drug use in the 6 weeks prior to first dose of study medication

          -  infection with HCV genotypes other than 2/3

          -  HIV infection

          -  HBV infection

          -  ongoing severe psychiatric disease

          -  frequent drug use that is judged by the treating physician to compromise treatment
             safety

          -  standard clinical and medical exclusions for treatment with pegylated interferon alfa
             2b and ribavirin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Dore, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olav Dalgard, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hunter Pharmacotherapy</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2300</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Penrith</city>
        <state>New South Wales</state>
        <zip>2751</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg / MSOC Free Clinic</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg / MSOC Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre Society</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Toronto Hepatitis C Program</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4M 3P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxiszentrum Im Tal (PIT)</name>
      <address>
        <city>Munich</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo/Akershus University hospitals</name>
      <address>
        <city>Oslo</city>
        <state>Lorenskog</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basel Zentrum fur Suchtmedizin</name>
      <address>
        <city>Basel</city>
        <zip>4057</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koda Bern/Poliklinik fur Infektiologe</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARUD, Poliklinik Zokl 1</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East London Foundation NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 31, 2015</lastchanged_date>
  <firstreceived_date>May 31, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>treatment</keyword>
  <keyword>injection drug users or receiving opiate substitution therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
